Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Taxotere